uploads///Graph

Imbruvica Is Key Growth Driver for AbbVie in Fiscal 2019

By

Jan. 29 2019, Updated 10:31 a.m. ET

Revenue performance in fiscal 2018

In the fourth quarter of 2018, AbbVie (ABBV) reported total sales of its hematologic oncology products of $1.13 billion, which is a YoY rise of 50.2% on a reported basis and 50.3% on an operational basis. This performance was mainly driven by robust demand for both Imbruvica and Venclexta.

The company reported hematologic oncology product sales of $929 million in the US market, a YoY rise of 51.0%. International markets contributed the remaining $201 million worth of sales, which is a YoY rise of 47.6% on an operational basis and 46.9% on a reported basis.

Article continues below advertisement

In fiscal 2018, AbbVie’s hematologic oncology portfolio reported global sales of $3.93 billion, a YoY rise of 45.9% on a reported basis and 45.8% on an operational basis. The company reported hematologic oncology product sales of $3.21 billion in the US market, a YoY rise of 43.9%. International markets contributed the remaining $719 million worth of sales, which is a YoY rise of 55.3% on an operational basis and 55.7% on a reported basis.

Imbruvica revenue performance

In the fourth quarter of 2018, AbbVie reported Imbruvica sales of $1.0 billion, a YoY rise of 42.0% on an operational and reported basis. According to the company’s fourth-quarter earnings conference call, this performance has been driven by solid uptake of the drug in frontline chronic lymphocytic leukemia (or CLL) indication.

The company reported Imbruvica sales of $839 million from the US market, a YoY rise of 43.2%. International markets contributed the remaining $167 million worth of Imbruvica sales, a YoY rise of 36.4% on an operational and reported basis. AbbVie expects Imbruvica to report sales close to $1.0 billion in the first quarter of 2019.

In fiscal 2018, AbbVie reported Imbruvica sales of $3.59 billion, a YoY rise of 39.5% on an operational and reported basis. The company reported Imbruvica sales of $2.97 billion from the US market, a YoY rise of 38.4%. International markets contributed the remaining $622 million worth of Imbruvica’s sales, a YoY rise of 45.0% on an operational and reported basis. AbbVie expects Imbruvica to report sales close to $4.4 billion in fiscal 2019.

In the next article, we’ll discuss the revenue performance of other key products of AbbVie in fiscal 2018.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.